Int. J. Curr. Res. Med. Sci. (2023). 9(11): 29-32

International Journal of Current Research in Medical Sciences

ISSN: 2454-5716

(A Peer Reviewed, Indexed and Open Access Journal)

www.ijcrims.com

Review Article

Volume 9, Issue 11 -2023

DOI: http://dx.doi.org/10.22192/ijcrms.2023.09.11.005

Mitigating Hemolysis in Pregnancy: Strategies for Managing Sickle Cell Anemia

***Emmanuel Ifeanyi Obeagu**

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

E-mail: emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug, 0000-0002-4538-0161

Abstract

Sickle Cell Anemia (SCA) poses significant challenges in pregnancy due to the potential exacerbation of hemolysis, impacting maternal and fetal health. This review consolidates current strategies and interventions aimed at mitigating hemolysis and managing SCA during pregnancy. We explore the complex interplay between pregnancy, SCA, and hemolysis, emphasizing the importance of tailored management approaches. Our review synthesizes evidence-based interventions, clinical guidelines, and emerging research to provide comprehensive insights into optimizing maternal and fetal outcomes in this vulnerable population.

Keywords: Sickle Cell Anemia, Pregnancy, Hemolysis, Maternal-Fetal Health, Management Strategies

Introduction

Sickle Cell Anemia (SCA) is a hereditary hemoglobinopathy characterized by abnormal hemoglobin, leading to hemolysis and a myriad of health complications [1-5]. Pregnancy complicates the management of SCA, elevating the risk of hemolysis-associated crises and adverse maternal-fetal outcomes [6-10]. While advancements in healthcare have improved outcomes for individuals with SCA, addressing the specific challenges during pregnancy remains a critical concern. This review aims to evaluate existing strategies and interventions focused on mitigating hemolysis and optimizing outcomes in pregnant women with SCA [11-15].

Pathophysiology of SCA in Pregnancy

The unique pathophysiological changes during pregnancy, such as increased blood volume and oxygen demands, often exacerbate hemolysis in individuals with SCA. This section elucidates the intricate mechanisms underlying hemolysis during pregnancy in SCA patients. Factors including increased oxidative stress, vaso-occlusive crises, and altered hemodynamic responses contribute to the heightened risk of complications [16-26].

Strategies for Mitigating Hemolysis

Emphasizing the importance of preconception counseling to optimize maternal health before pregnancy, including genetic counseling, folic acid supplementation, and disease-modifying therapies.Tailored prenatal care focusing on close monitoring, early detection of complications, and multidisciplinary interventions involving hematologists, obstetricians, and other specialists.Reviewing the efficacy and safety of hydroxyurea in pregnant women with SCA, considering its potential role in reducing hemolysis and associated complications.Exploring the indications and challenges associated with blood transfusions in managing anemia and preventing complications during pregnancy.Discussing strategies for pain management and crisis prevention, including the role of analgesics, hydration, and rest [27-33.

Challenges and Future Directions

Addressing the existing challenges in managing hemolysis in pregnant women with SCA, such as limited access to specialized care, ethical considerations, and medication safety. Additionally, highlighting the need for further research into novel therapeutic approaches and personalized medicine to improve outcomes in this population [34-36].

Conclusion

Managing hemolysis in pregnant women with SCA is a multifaceted challenge requiring a comprehensive and multidisciplinary approach. By synthesizing current evidence and highlighting effective strategies, this review aims to guide clinicians and healthcare providers in optimizing care for this vulnerable population, ultimately improving maternal and fetal outcomes.

References

1. Fasano RM, Meier ER, Chonat S. Sickle cell disease, thalassemia, and hereditary hemolytic anemias. Rossi's Principles of Transfusion Medicine. 2022 Aug 23:326-45.
2. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):2244-52.
3. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-8.
4. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-1.
5. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
6. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):12-7.
7. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. Migration. 2023;17:18.
8. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018;5:157-8.
9. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487.
10. Obeagu EI, Getrude U. Obeagu.,(2023). Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.;6(1):2768-0487.
11. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-9.
12. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023 Dec 1;102(48):e36462.
13. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence Of The Sickle Cell Trait Among Undergraduate Students

Of The University Of Calabar. Prevalence.;5(100):0-5.
14. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
15. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-4.
16. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU. Anaemia in children under five years: African perspectives. Int. J. Curr. Res. Biol. Med. 2023;1:1-7.
17. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-5.
18. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-3.
19. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-8.
20. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-34.
21. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015 Jan 10;8(3):261-5.
22. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2023 Jan 1;3(1):1-6.
23. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-7.
24. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. ASSESSMENT OF FACTORS PRECIPITATING SICKLE CELL CRISES AMONG UNDER 5-YEARS CHILDREN ATTENDING SICKLE CELL CLINIC OF MURTALA MUHAMMAD SPECIALIST HOSPITAL, KANO. blood. 2023;11:16.
25. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
26. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research. 2023;6(1):2768-0487.
27. Smith-Whitley K. Complications in pregnant women with sickle cell disease. Hematology 2014, the American Society of Hematology Education Program Book. 2019 Dec 6;2019(1):359-66.
28. Sammaritano LR. Contraception and preconception counseling in women with autoimmune disease. Best Practice & Research Clinical Obstetrics & Gynaecology. 2020 Apr 1;64:11-23.
29. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-4.
30. Gamde MS, Obeagu EI. Iron Deficiency Anaemia: Enemical to Pregnancy. European Journal of Biomedical. 2023;10(9):272-5.
31. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10; 6 (2): 10-3.
32. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-5.

33. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-5.
34. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Jama. 2014 Sep 10;312(10):1033-48.
35. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-5.
36. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep

Access this Article in Online	
	Website: www.ijcrims.com
Quick Response Code	Subject: Medical Sciences

How to cite this article:
Emmanuel Ifeanyi Obeagu. (2023). Mitigating Hemolysis in Pregnancy: Strategies for Managing Sickle Cell Anemia. Int. J. Curr. Res. Med. Sci. 9(11): 29-32.
DOI: http://dx.doi.org/10.22192/ijcrms.2023.09.11.005